290 related articles for article (PubMed ID: 34150608)
1. Epithelial-Mesenchymal-Transition-Like Circulating Tumor Cell-Associated White Blood Cell Clusters as a Prognostic Biomarker in HR-Positive/HER2-Negative Metastatic Breast Cancer.
Guan X; Li C; Li Y; Wang J; Yi Z; Liu B; Chen H; Xu J; Qian H; Xu B; Ma F
Front Oncol; 2021; 11():602222. PubMed ID: 34150608
[TBL] [Abstract][Full Text] [Related]
2. The prognostic and therapeutic implications of circulating tumor cell phenotype detection based on epithelial-mesenchymal transition markers in the first-line chemotherapy of HER2-negative metastatic breast cancer.
Guan X; Ma F; Li C; Wu S; Hu S; Huang J; Sun X; Wang J; Luo Y; Cai R; Fan Y; Li Q; Chen S; Zhang P; Li Q; Xu B
Cancer Commun (Lond); 2019 Jan; 39(1):1. PubMed ID: 30606259
[TBL] [Abstract][Full Text] [Related]
3. Prognostic impact of circulating tumor cell apoptosis and clusters in serial blood samples from patients with metastatic breast cancer in a prospective observational cohort.
Jansson S; Bendahl PO; Larsson AM; Aaltonen KE; Rydén L
BMC Cancer; 2016 Jul; 16():433. PubMed ID: 27390845
[TBL] [Abstract][Full Text] [Related]
4. Post-therapeutic circulating tumor cell-associated white blood cell clusters predict poor survival in patients with advanced driver gene-negative non-small cell lung cancer.
Wang Y; Liu Y; Zhang Z; Lu B; Gao Y; Tong L; Hu M; Lin PP; Li B; Zhang T
BMC Cancer; 2023 Jun; 23(1):578. PubMed ID: 37349714
[TBL] [Abstract][Full Text] [Related]
5. Analysis of the prognostic role and biological characteristics of circulating tumor cell-associated white blood cell clusters in non-small cell lung cancer.
Li Z; Fan L; Wu Y; Niu Y; Zhang X; Wang B; Yao Y; Chen C; Qi N; Wang DD; Lin PP; Tang D; Gao W
J Thorac Dis; 2022 May; 14(5):1544-1555. PubMed ID: 35693614
[TBL] [Abstract][Full Text] [Related]
6. Circulating tumor cell associated white blood cell cluster as a biomarker for metastasis and recurrence in hepatocellular carcinoma.
Chen J; Luo Y; Xi X; Li H; Li S; Zheng L; Yang D; Cai Z
Front Oncol; 2022; 12():931140. PubMed ID: 36465354
[TBL] [Abstract][Full Text] [Related]
7. Circulating Tumor Cells with Stemness and Epithelial-to-Mesenchymal Transition Features Are Chemoresistant and Predictive of Poor Outcome in Metastatic Breast Cancer.
Papadaki MA; Stoupis G; Theodoropoulos PA; Mavroudis D; Georgoulias V; Agelaki S
Mol Cancer Ther; 2019 Feb; 18(2):437-447. PubMed ID: 30401696
[TBL] [Abstract][Full Text] [Related]
8. Longitudinal enumeration and cluster evaluation of circulating tumor cells improve prognostication for patients with newly diagnosed metastatic breast cancer in a prospective observational trial.
Larsson AM; Jansson S; Bendahl PO; Levin Tykjaer Jörgensen C; Loman N; Graffman C; Lundgren L; Aaltonen K; Rydén L
Breast Cancer Res; 2018 Jun; 20(1):48. PubMed ID: 29884204
[TBL] [Abstract][Full Text] [Related]
9. Prognostic value of circulating tumor cells associated with white blood cells in solid cancer: a systematic review and meta-analysis of 1471 patients with solid tumors.
Ju M; Gao Z; Gu G; Huang H; Sun A; Zheng C; Li H; Zhang Y; Li K
BMC Cancer; 2023 Dec; 23(1):1224. PubMed ID: 38087278
[TBL] [Abstract][Full Text] [Related]
10. The potential of using circulating tumour cells and their gene expression to predict docetaxel response in metastatic prostate cancer.
Davies CR; Guo T; Burke E; Stankiewicz E; Xu L; Mao X; Scandura G; Rajan P; Tipples K; Alifrangis C; Wimalasingham AG; Galazi M; Crusz S; Powles T; Grey A; Oliver T; Kudahetti S; Shaw G; Berney D; Shamash J; Lu YJ
Front Oncol; 2022; 12():1060864. PubMed ID: 36727071
[TBL] [Abstract][Full Text] [Related]
11. Circulating Tumor-Cell-Associated White Blood Cell Clusters in Peripheral Blood Indicate Poor Prognosis in Patients With Hepatocellular Carcinoma.
Luo Q; Wang C; Peng B; Pu X; Cai L; Liao H; Chen K; Zhang C; Cheng Y; Pan M
Front Oncol; 2020; 10():1758. PubMed ID: 33224869
[No Abstract] [Full Text] [Related]
12. Circulating tumor cells as a prognostic marker for efficacy in the randomized phase III JO21095 trial in Japanese patients with HER2-negative metastatic breast cancer.
Iwata H; Masuda N; Yamamoto D; Sagara Y; Sato N; Yamamoto Y; Saito M; Fujita T; Oura S; Watanabe J; Tsukabe M; Horiguchi K; Hattori S; Matsuura Y; Kuroi K
Breast Cancer Res Treat; 2017 Apr; 162(3):501-510. PubMed ID: 28181129
[TBL] [Abstract][Full Text] [Related]
13. Circulating tumor cells (CTCs)/circulating tumor endothelial cells (CTECs) and their subtypes in small cell lung cancer: Predictors for response and prognosis.
Zhu HH; Liu YT; Feng Y; Zhang LN; Zhang TM; Dong GL; Xing PY; Wang HY; Shi YK; Hu XS
Thorac Cancer; 2021 Oct; 12(20):2749-2757. PubMed ID: 34423906
[TBL] [Abstract][Full Text] [Related]
14. The prognostic value of chemotherapy or endocrine therapy choice according to circulating tumor cell count in HR
Shao B; Li H; Zhang J; Liu X; Song G; Jiang H; Yan Y; Wang H; Wang J; Di L
Ann Transl Med; 2022 Aug; 10(16):901. PubMed ID: 36111005
[TBL] [Abstract][Full Text] [Related]
15. Clinical Significance of Circulating Tumor Cells in Hormone Receptor-positive Metastatic Breast Cancer Patients who Received Letrozole with or Without Bevacizumab.
Magbanua MJM; Savenkov O; Asmus EJ; Ballman KV; Scott JH; Park JW; Dickler M; Partridge A; Carey LA; Winer EP; Rugo HS
Clin Cancer Res; 2020 Sep; 26(18):4911-4920. PubMed ID: 32586939
[TBL] [Abstract][Full Text] [Related]
16. [Value of serum human epithelial growth factor receptor 2 extracellular domain and circulating tumor cells in evaluating therapeutic response in advanced gastric cancer].
Li Y; Peng Z; Zhang X; Gong J; Shen L
Zhonghua Wei Chang Wai Ke Za Zhi; 2017 Nov; 20(11):1293-1299. PubMed ID: 29178102
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of Circulating Tumor Cell Count-Driven vs Clinician-Driven First-line Therapy Choice in Hormone Receptor-Positive, ERBB2-Negative Metastatic Breast Cancer: The STIC CTC Randomized Clinical Trial.
Bidard FC; Jacot W; Kiavue N; Dureau S; Kadi A; Brain E; Bachelot T; Bourgeois H; Gonçalves A; Ladoire S; Naman H; Dalenc F; Gligorov J; Espié M; Emile G; Ferrero JM; Loirat D; Frank S; Cabel L; Diéras V; Cayrefourcq L; Simondi C; Berger F; Alix-Panabières C; Pierga JY
JAMA Oncol; 2021 Jan; 7(1):34-41. PubMed ID: 33151266
[TBL] [Abstract][Full Text] [Related]
18. Expression of stem cell and epithelial-mesenchymal transition markers in primary breast cancer patients with circulating tumor cells.
Kasimir-Bauer S; Hoffmann O; Wallwiener D; Kimmig R; Fehm T
Breast Cancer Res; 2012 Jan; 14(1):R15. PubMed ID: 22264265
[TBL] [Abstract][Full Text] [Related]
19. Analysis of the hormone receptor status of circulating tumor cell subpopulations based on epithelial-mesenchymal transition: a proof-of-principle study on the heterogeneity of circulating tumor cells.
Guan X; Ma F; Liu S; Wu S; Xiao R; Yuan L; Sun X; Yi Z; Yang H; Xu B
Oncotarget; 2016 Oct; 7(40):65993-66002. PubMed ID: 27602758
[TBL] [Abstract][Full Text] [Related]
20. Prospective assessment of the prognostic value of circulating tumor cells and their clusters in patients with advanced-stage breast cancer.
Mu Z; Wang C; Ye Z; Austin L; Civan J; Hyslop T; Palazzo JP; Jaslow R; Li B; Myers RE; Jiang J; Xing J; Yang H; Cristofanilli M
Breast Cancer Res Treat; 2015 Dec; 154(3):563-71. PubMed ID: 26573830
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
